Search results
Earnings call: Fate Therapeutics reports on clinical progress and finances By Investing.com
Investing.com· 3 days agoThe company's FT819 CAR T-cell therapy showed promise for B-cell-mediated autoimmune diseases, with...
Citi raises Prime Medicine shares target on FDA Milestone By Investing.com
Investing.com· 7 hours agoThe upgrade follows the recent announcement by Prime that the FDA has cleared an Investigational New...
US FDA approves expanded use of Bristol's cancer cell therapy
Reuters via Yahoo Finance· 19 hours agoMay 15 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi to ...
Thermo Fisher (TMO) Unveils New Extended Blood Genotyping Array
Zacks via Yahoo Finance· 3 hours agoThermo Fisher's (TMO) new Applied Biosystems Axiom BloodGenomiX Array and Software provide a...
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Yucaipa News Mirror· 2 days agoKyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, ...
Breakthrough therapies are saving lives. Can we afford them?
San Jose Mercury News· 4 days agoLast month, Stanford became the first hospital in the nation to use a new $515,000 cell therapy to...
Breakthrough therapies are saving lives, but can we afford them?
Medical Xpress· 3 days agoLast month, Stanford became the first hospital in the nation to use a new $515,000 cell therapy to...
Treatments for lymphoma have advanced beyond chemotherapy - UPI.com
UPI· 55 minutes agoTreatment for blood cancers can include chemotherapy alone or chemo in conjunction with cutting edge...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 19 hours agoPreliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell
Thermo Fisher (TMO) Unveils New Extended Blood Genotyping Array
Zacks· 11 hours agoFree Report) recently introduced the Applied Biosystems Axiom BloodGenomiX Array and Software, a first-of-its-kind solution for more precise blood genotyping in clinical research. The new array ...